Not logged in Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness Metzger-Filho, Otto; Collier, Katharine; Asad, Sarah; Ansell, Peter J.; Watson, Mark; Bae, Junu; Cherian, Mathew; O'Shaughnessy, Joyce; Untch, Michael; Rugo, Hope S.; Huober, Jens B.; Golshan, Mehra; Sikov, William M.; von Minckwitz, Gunter; Rastogi, Priya; Li, Lang; Cheng, Lijun; Maag, David; Wolmark, Norman; Denkert, Carsten; Symmans, W. Fraser; Geyer, Charles E., Jr.; Loibl, Sibylle; Stover, Daniel G. Share Save
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE Mamounas, E. P.; Untch, M.; Mano, M. S.; Huang, C-S; Geyer, C. E., Jr.; von Minckwitz, G.; Wolmark, N.; Pivot, X.; Kuemmel, S.; DiGiovanna, M. P.; Kaufman, B.; Kunz, G.; Conlin, A. K.; Alcedo, J. C.; Kuehn, T.; Wapnir, I; Fontana, A.; Hackmann, J.; Polikoff, J.; Saghatchian, M.; Brufsky, A.; Yang, Y.; Zimovjanova, M.; Boulet, T.; Liu, H.; Tesarowski, D.; Lam, L. H.; Song, C.; Smitt, M.; Loibl, S. Share Save
Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+breast cancer: Subgroup analysis from KATHERINE Loibl, S.; Huang, C-S.; Mano, M. S.; Mamounas, T. P.; Geyer, C. E.; Untch, M.; von Minckwitz, G.; Thery, J. -C.; Schwaner, I.; Limentani, S.; Loman, N.; Lubbe, K.; Chang, J. C.; Hatschek, T.; Tesarowski, D.; Boulet, T.; Wiese, C.; Song, C.; Wolmark, N. Share Save
Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer Conte, PierFranco; Schneeweiss, Andreas; Loibl, Sibylle; Mamounas, Eleftherios P.; von Minckwitz, Gunter; Mano, Max S.; Untch, Michael; Huang, Chiun-Sheng; Wolmark, Norman; Rastogi, Priya; D'Hondt, Veronique; Redondo, Andres; Stamatovic, Ljiljana; Bonnefoi, Herve; Castro-Salguero, Hugo; Fischer, Hans H.; Wahl, Tanya; Song, Chunyan; Boulet, Thomas; Trask, Peter; Geyer, Charles E., Jr. Share Save
Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer Surgical Results From the BrighTNess Randomized Clinical Trial Golshan, Mehra; Loibl, Sibylle; Wong, Stephanie M.; Houber, Jens Bodo; O'Shaughnessy, Joyce; Rugo, Hope S.; Wolmark, Norman; McKee, Mark D.; Maag, David; Sullivan, Danielle M.; Metzger-Filho, Otto; Von Minckwitz, Gunter; Geyer, Charles E., Jr.; Sikov, William M.; Untch, Michael Share Save
Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC) Loibl, Sibylle; Untch, Michael; Buyse, Marc; Robidoux, Andre; Gianni, Luca; Schneeweiss, Andreas; Conte, Pierfranco; Piccart, Martine; Bonnefoi, Herve; Jackisch, Christian; Nekljudova, Valentina; Costantino, Joseph; Valagussa, Pinuccia; Neate, Colin; Gelber, Richard; Poncet, Coralie; Squifflet, Pierre; Saad, Everardo; Heinzmann, Dominik; Denkert, Carsten; Geyer, Charles E., Jr.; Cortes, Javier; Guarneri, Valentina; de Azambuja, Evandro; Cameron, David; Ismael, Gustavo; von Minckwitz, Gunter; Wolmark, Norman; Cortazar, Patricia Share Save
Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis Mano, Max S.; Loibl, Sibylle; Mamounas, Eleftherios P.; von Minckwitz, Gunter; Huang, Chiun-Sheng; Untch, Michael; Wolmark, Norman; Wapnir, Irene L.; Yang, Youngsen; Conlin, Alison K.; Kuemmel, Sherko; Saghatchian, Mahasti; DiGiovanna, Michael P.; Strunk, Claudia; Zimovjanova, Martina; Song, Chunyan; Liu, Haying; Tesarowski, David; Blotner, Steven; Lam, Lisa H.; Smitt, Melanie; Geyer, Charles E., Jr. Share Save
Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial Golshan, Mehra; Wong, Stephanie M.; Loibl, Sibylle; Huober, Jens Bodo; O'Shaughnessy, Joyce; Rugo, Hope S.; Wolmark, Norman; Ansell, Peter; Maag, David; Sullivan, Danielle M.; Metzger-Filho, Otto; Von Minckwitz, Gunter; Geyer, Charles E., Jr.; Sikov, William M.; Untch, Michael Share Save
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy Sinn, Bruno Valentin; Weber, Karsten E.; Schmitt, Wolfgang Daniel; Fasching, Peter A.; Symmans, William Fraser; Blohmer, Jens-Uwe; Karn, Thomas; Taube, Eliane Tabea; Klauschen, Frederick; Marme, Frederik; Schem, Christian; Stickeler, Elmar; Ataseven, Beyhan; Huober, Jens; von Minckwitz, Gunter; Seliger, Barbara; Denkert, Carsten; Loibl, Sibylle Share Save
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study Loibl, S.; Untch, M.; Burchardi, N.; Huober, J.; Sinn, B., V; Blohmer, J-U; Grischke, E-M; Furlanetto, J.; Tesch, H.; Hanusch, C.; Engels, K.; Rezai, M.; Jackisch, C.; Schmitt, W. D.; von Minckwitz, G.; Thomalla, J.; Kuemmel, S.; Rautenberg, B.; Fasching, P. A.; Weber, K.; Rhiem, K.; Denkert, C.; Schneeweiss, A. Share Save
Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials Krug, David; Lederer, Bianca; Seither, Fenja; Nekljudova, Valentina; Ataseven, Beyhan; Blohmer, Jens-Uwe; Costa, Serban Dan; Denkert, Carsten; Ditsch, Nina; Gerber, Bernd; Hanusch, Claus; Heil, Joerg; Hilfrich, Joern; Huober, Jens B.; Jackisch, Christian; Kuemmel, Sherko; Paepke, Stefan; Schem, Christian; Schneeweiss, Andreas; Untch, Michael; Debus, Juergen; von Minckwitz, Gunter; Kuehn, Thorsten; Loibl, Sibylle Share Save
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial Loibl, Sibylle; Treue, Denise; Budczies, Jan; Weber, Karsten; Stenzinger, Albrecht; Schmitt, Wolfgang D.; Weichert, Wilko; Jank, Paul; Furlanetto, Jenny; Klauschen, Frederick; Karn, Thomas; Pfarr, Nicole; von Minckwitz, Gunter; Moebs, Markus; Jackisch, Christian; Sers, Christine; Schneeweiss, Andreas; Fasching, Peter A.; Schem, Christian; Hummel, Michael; van Mackelenbergh, Marion; Nekljudova, Valentina; Untch, Michael; Denkert, Carsten Share Save
Fatal events during clinical trials: an evaluation of deaths during breast cancer studies Furlanetto, Jenny; von Minckwitz, Gunter; Lederer, Bianca; Moebus, Volker; Schneeweiss, Andreas; Huober, Jens; Fasching, Peter A.; Gerber, Bernd; Bauerfeind, Ingo; Nitz, Ulrike; Lueck, Hans-Joachim; Hanusch, Claus; Thomssen, Christoph; Untch, Michael; Nekljudova, Valentina; Mehta, Keyur; Loibl, Sibylle Share Save
Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto Laakmann, Elena; Witzel, Isabel; Fasching, Peter A.; Rezai, Mandi; Schem, Christian; Solbach, Christine; Tesch, Hans; Klare, Peter; Schneeweiss, Andreas; Salat, Christoph; Zahm, Dirk-Michael; Blohmer, Jens-Uwe; Ingold-Heppner, Barbara; Huober, Jens; Hanusch, Claus; Jackisch, Christian; Reinisch, Mattea; Untch, Michael; von Minckwitz, Gunter; Nekljudova, Valentina; Mueller, Volkmar; Loibl, Sibylle Share Save
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII+IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial Denkert, Carsten; Budczies, Jan; Regan, Meredith M.; Loibl, Sibylle; Dell'Orto, Patrizia; von Minckwitz, Gunter; Mastropasqua, Mauro G.; Solbach, Christine; Thurlimann, Beat; Mehta, Keyur; Blohmer, Jens-Uwe; Colleoni, Marco; Mueller, Volkmar; Klauschen, Frederick; Ataseven, Beyhan; Engels, Knut; Kammler, Roswitha; Pfitzner, Berit M.; Dietel, Manfred; Fasching, Peter A.; Viale, Giuseppe Share Save
PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial Chia, Stephen K. L.; Martin, Miguel; Holmes, Frankie A.; Ejlertsen, Bent; Delaloge, Suzette; Moy, Beverly; Iwata, Hiroji; von Minckwitz, Gunter; Mansi, Janine; Barrios, Carlos H.; Gnant, Michael; Tomasevic, Zorica; Denduluri, Neelima; Separovic, Robert; Kim, Sung-Bae; Jakobsen, Erik Hugger; Harvey, Vernon; Robert, Nicholas; Smith, John, II; Harker, Graydon; Zhang, Bo; Eli, Lisa D.; Ye, Yining; Lalani, Alshad S.; Buyse, Marc; Chan, Arlene Share Save
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial Janning, Melanie; Mueller, Volkmar; Vettorazzi, Eik; Cubas-Cordova, Miguel; Gensch, Victoria; Ben-Batalla, Isabel; zu Eulenburg, Christine; Schem, Christian; Fasching, Peter A.; Schnappauf, Benjamin; Karn, Thomas; Fehm, Tanja; Just, Marianne; Kuehn, Thorsten; Holms, Frank; Overkamp, Friedrich; Krabisch, Petra; Rack, Brigitte; Denkert, Carsten; Untch, Michael; Tesch, Hans; Rezai, Mahdi; Kittel, Kornelia; Pantel, Klaus; Bokemeyer, Carsten; Loibl, Sibylle; von Minckwitz, Gunter; Loges, Sonja Share Save
Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab-based adjuvant therapy in HER2+early-stage breast cancer: Subgroup analyses from the phase III ExteNET trial Gnant, M.; Martin, M.; Holmes, F-A; Jackisch, C.; Chia, S. K.; Iwata, H.; Moy, B.; Martinez, N.; Mansi, J.; Morales, S.; Ruiz-Borrego, M.; von Minckwitz, G.; Buyse, M.; Delaloge, S.; Bhandari, M.; Rosales, A. Murias; Galeano, T.; Fujita, T.; Luczak, A.; Barrios, C. H.; Saura, C.; Rugo, H. S.; Chien, J.; Johnston, S. R.; Spencer, M.; Xu, F.; Barnett, B.; Chan, A.; Ejlertsen, B. Share Save
Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE Geyer, C. E., Jr.; Huang, C-S; Mano, M. S.; Loibl, S.; Mamounas, E. P.; Untch, M.; Wolmark, N.; Rastogi, P.; Fischer, H. H.; Redondo, A.; Jackisch, C.; Jacot, W.; Conlin, A. K.; Schneeweiss, A.; Wapnir, I. L.; Fasching, P. A.; DiGiovanna, M. P.; Wuelfing, P.; Arce-Salinas, C.; Crown, J. P.; Shao, Z.; Caremoli, E. Rota; Wu, H.; Lam, L. H.; Tesarowski, D.; Smitt, M.; Douthwaite, H.; Singel, S. M.; von Minckwitz, G. Share Save
mRNA signatures predict response to durvalumab therapy in triple negative breast cancer (TNBC) Results of the translational biomarker programme of the neoadjuvant double-blind placebo controlled GeparNuevo trial Loibl, S.; Sinn, B. V.; Karn, T.; Untch, M.; Treue, D.; Sinn, H-P; Weber, K. E.; Hanusch, C. A.; Fasching, P. A.; Huober, J.; Zahm, D-M; Jackisch, C.; Thomalla, J.; Blohmer, J-U; Marme, F.; Klauschen, F.; Rhiem, K.; Felder, B.; von Minckwitz, G.; Burchardi, N.; Schneeweiss, A.; Denkert, C. Share Save
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
CANCER RESEARCH.png)
.png){kind=icon}
Share.png){kind=icon}
Save